

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




MP66362

B 37

INTEI

(51) International Patent Classification 5: C07D 215/20, 213/65, 271/12, 295/08, A61K 31/495		A1	(11) International Publication Number: WO 94/24107 (43) International Publication Date: 27 October 1994 (27.10.94)
(21) International Application Number: PCT/US94/04215 (22) International Filing Date: 13 April 1994 (13.04.94) (30) Priority Data: 08/049,065 19 April 1993 (19.04.93) US (71) Applicant: SYNTEX (U.S.A.) INC. (US/US); 3401 Hillview Avenue, Palo Alto, CA 94304 (U.S.). (72) Inventors: PFISTER, Jurg, Roland; 1500 Oak Avenue, Los Altos, CA 94024 (US); SLATE, Doris, Lynne; 210 Sleeper Avenue, Mountain View, CA 94043 (US). (74) Agents: VON MORZE, Herwig et al.; Syntex (U.S.A.) Inc., 3401 Hillview Avenue, A2-200, Palo Alto, CA 94304 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: 10,11-METHANODIBENZOSUBERANE DERIVATIVES USED AS CHEMOSENSITIZING AGENTS



(57) Abstract

10,11-Methanodibenzosuberane derivatives, i.e., the compounds of formula (I), wherein A is $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CHR}^a\text{CH}_2-$, or $-\text{CHR}^a\text{CHR}^b\text{CH}_2-$, where one of R^a or R^b is H, OH, or lower alkoxy, and the other is H; R^1 is H, F, Cl or Br; R^2 is H, F, Cl or Br; and R^3 is heteroaryl or phenyl optionally substituted with F, Cl, Br, CF_3 , CN, NO_2 or OCH_2F ; and the pharmaceutically acceptable salts thereof, are useful chemosensitizing agents, e.g., for cancer chemotherapy, particularly for treating multidrug resistance.

10,11-METHANODIBENZOSUBERANE DERIVATIVES USED AS CHEMOSENSITIZING AGENTS

5 Field of the Invention

The present invention relates to pharmaceutically active agents. These agents are useful e.g., for the treatment of cancer, in particular for enhancing the efficacy of existing cancer chemotherapeutics and for treating multidrug resistance. More specifically, the invention relates to a series of 10,11-methanodibenzosuberane derivatives. The invention is also directed to pharmaceutical formulations and chemosensitizing methods, e.g., for treating cancer including the reversal of multidrug resistance, to uses of the new agents in the preparation of pharmaceutical compositions comprising these agents and to methods of their preparation.

15 Background Information


Among the problems faced in cancer chemotherapy is the development of resistance to treatment regimens. Tumors that respond well to a particular drug or drugs initially, often develop a tolerance to the drug(s). This disease state, called multi-drug resistance, is discussed in greater detail in Kuzmich and Tew, "Detoxification Mechanisms and Tumor Cell Resistance to Anticancer Drugs," particularly section VII "The Multidrug-Resistant Phenotype (MDR)," *Medical Research Reviews*, Vol. 11, No. 2, 185-217, particularly 208-213 (1991); and in Georges, Sharom and Ling, "Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer Chemotherapy," *Advances in Pharmacology*, Vol. 21, 185-220 (1990).

Certain active agents, called chemosensitizing agents or potentiating agents, have been suggested as resistance modifying agents for treating multidrug resistance, but have suffered from various disadvantageous properties. These have included, e.g., verapamil (a calcium entry blocker that lowers blood pressure and has also been found effective in vitro for treating drug-resistant malaria), steroids, trifluoperazine (a CNS agent), vindoline, and reserpine (an α -2 blocker with CNS properties). Thus, there has remained a need for active agents to treat, i.e., reverse, inhibit and/or prevent multidrug resistance, preferably with minimal or no adverse side effects.

Chemosensitizing agents interact with P-glycoprotein, a drug efflux pump found in cell membranes, particularly those of multidrug resistant tumor cells, gastrointestinal tract cells, and the endothelial cells that form the blood brain barrier. By blocking this pump, chemosensitizing agents inhibit the efflux of cancer chemotherapeutic drugs from tumor cells, and can enhance permeation of nutrients or active agents through the gastrointestinal tract, and the permeation of active agents through the blood brain barrier.

U.S. Patent No. 5,112,817 to Fukasawa et al. discloses certain quinoline derivatives useful as anticancer drug potentiators for the treatment of multidrug resistance. One of the initially promising active agents there-disclosed is MS-073, which has the following structure:

-2-




MS-073

While highly active in *in vitro* testing, MS-073 was, however, found to have poor oral bioavailability and to suffer from instability problems in solution. Other compounds of the series, such as the biphenylmethyl-carbonyl derivative MS-209, have been found to have better stability and oral bioavailability, but, at the cost of having to administer higher effective doses. Thus, the problem exists to provide an anticancer drug potentiator having the activity of MS-073, together with good oral bioavailability and stability. The present invention aims to addressing that problem.

SUMMARY OF THE INVENTION

One aspect of the present invention concerns 10,11-methano-dibenzosuberane derivatives, i.e., the compounds of Formula I:



Formula I

- 3 -

wherein:

A is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CHR}^a-\text{CH}_2-$, or $-\text{CH}_2-\text{CHR}^b-\text{CHR}^c-\text{CH}_2-$, where one of R^a or R^b is H, OH, or lower alkoxy, and the other is H;

R^1 is H, F, Cl or Br;

5 R^2 is H, F, Cl or Br; and

R^3 is heteroaryl or phenyl optionally substituted with F, Cl, Br, CF_3 , CN, NO_2 or OCH_3 ;

and the pharmaceutically acceptable salts thereof.

10 In a preferred aspect, the invention relates to certain compounds of Formula I, and in particular to the single isomers thereof, particularly including the compound where A is $-\text{CH}_2-\text{CHR}^a-\text{CH}_2-$ where R^a is OH, R^1 is F, R^2 is F, and R^3 is quinolyl. Most preferred is the (2R)-anti isomer.

15 In another aspect, the invention relates to a pharmaceutical composition containing a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. In a preferred embodiment, such a pharmaceutical composition will also include a pharmaceutically acceptable excipient.

20 In still another aspect, the invention relates to a method of treatment by administering to a mammal in need of such treatment a compound of Formula I or a pharmaceutically acceptable salt thereof or the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition, in an amount therapeutically effective to potentiate the efficacy of a co-administered cancer chemotherapeutic agent. Examples of such cancer chemotherapeutic agents are
25 antimetabolites such as 6-mercaptopurine, 5-fluorouracil, cytosine arabinoside and their metabolites and derivatives of these agents. Other cancer chemotherapeutic agents are antifolates such as methotrexate or agents derived from natural products, for example, derived from vinca alkaloids such as vinblastine, vincristine and colchicine; adriamycin, daunorubicin, doxorubicin, teniposide or etoposide. Such cancer
30 chemotherapeutic agents also include platinum anticancer drugs, such as cisplatin and carboplatin. In addition, the agents of the present invention can be administered with cyclophosphamide, busulfone, procarbazine, dacarbazine, carmustine, lomustine, mechlorethamine, chlorambucil, hydroxyurea, melphalan, mitotone, taxol and spirogermanium. Most commonly
35 multidrug resistance is observed with the vinca alkaloids, the anthracyclines daunorubicin, doxorubicin and adriamycin; and etoposide and teniposide; less frequently with antimetabolites and the other chemotherapeutic agents.

40 In yet another aspect, the invention relates to a method of treating drug resistance in a mammal, by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. One embodiment of this aspect entails a method of treating drug-resistant malaria. In a preferred

embodiment, a method of treating multidrug resistant cancer in a mammal evidencing clinical resistance to a cancer chemotherapeutic agent, a resistance modifying amount of a compound or salt of Formula I is co-administered with a therapeutically effective amount of the cancer chemotherapeutic agent to which resistance has been evidenced.

In still another aspect the invention relates to a chemosensitizing method for enhancing bioavailability of a pharmaceutically active agent comprising administering to a mammal in need thereof an amount of a compound or salt of Formula I sufficient to increase permeation of an active agent through the blood-brain barrier or the gastrointestinal tract.

In still another aspect the invention relates to a process for preparing the compounds of Formula I.

DETAILED DESCRIPTION OF THE INVENTION

Definitions and General Parameters

The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

The term "alkyl" refers to a fully saturated monovalent radical containing only carbon and hydrogen, and which may be a cyclic, branched or straight chain radical. This term is further exemplified by radicals such as methyl, ethyl, t-butyl, pentyl, neopentyl, heptyl and adamantyl.

The term "lower alkyl" refers to a cyclic, branched or straight chain monovalent alkyl radical of one to six carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, i-butyl (or 2-methylpropyl), cyclopropylmethyl, i-amyl, n-amyl, and hexyl.

The term "alkylene" refers to a fully saturated divalent radical containing only carbon and hydrogen, and which may be a branched or straight chain radical. This term is further exemplified by radicals such as methylene, ethylene, n-propylene, t-butylene, i-pentylene, and n-heptylene.

The term "lower alkylene" refers to a divalent alkyl radical of one to six carbon atoms. This term is further exemplified by such radicals as methylene, ethylene, n-propylene, i-propylene, n-butylene, t-butylene, i-butylene (or 2-methylpropylene), isoamylenes, pentylenes, and n-hexylene.

The term "lower acyloxy" refers to the group -O-C(O)-R' where R' is lower alkyl.

The term "aryl" refers to a monovalent unsaturated aromatic carbocyclic radical typically with 6 to 16 carbon atoms having a single ring (e.g., phenyl) or two condensed rings (e.g., naphthyl), which can optionally be mono-, di- or tri-substituted, independently, with fluoro, chloro, bromo, trifluoromethyl, cyano, nitro and/or difluoromethoxy.

The term "heteroaryl" refers to a monovalent unsaturated aromatic

heterocyclic radical typically with 2 to 12 carbon atoms having at least one hetero atom, typically from 1 to 3 heteroatoms such as N, O or S, within the ring. The heteroaryl radical will typically have a single ring, such as pyridyl, or two condensed rings, such as quinolyl, benzofuranyl, and benzofurazanyl.

The term "halo" refers to fluoro, bromo, chloro and iodo.

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.

A "pharmaceutically acceptable salt" may be any salt derived from an inorganic or organic acid. The term "pharmaceutically acceptable anion" refers to the anion of such acid addition salts. The salt and/or the anion are chosen not to be biologically or otherwise undesirable.

The anions are derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid (giving the sulfate and bisulfate salts), nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, p-toluenesulfonic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, lactic acid, o-(4-hydroxy-benzoyl)benzoic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis(3-hydroxy-2-naphthoic) acid, 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, laurylsulfuric acid, glucuronic acid, glutamic acid, 3-hydroxy-2-naphthoic acid, stearic acid, muconic acid and the like.

The term "treatment" or "treating" means any treatment of a disease in a mammal, including:

- (i) preventing the disease, that is, causing the clinical symptoms of the disease not to develop;
- (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or
- (iii) relieving the disease, that is, causing the regression of clinical symptoms.

The term "effective amount" means a dosage sufficient to provide treatment for the disease state being treated. This will vary depending on the patient, the disease and the treatment being effected.

The term "co-administer" means the administration of more than one active agent as part of the same treatment regimen, whether they are administered simultaneously or at different times.

"Structure of Formula I" refers to the generic structure of the

compounds of the invention. The chemical bonds indicated as with a wavy line, e.g., in Formula II indicate nonspecific stereochemistry, e.g. at position 5 of the dibenzosuberane, i.e., the carbon to which is attached the piperazine group.

5 "Isomerism" refers to compounds having the same atomic mass and atomic number but differing in one or more physical or chemical properties.

"Stereoisomer" refers to one of two chemical compounds having the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped differently. That is, certain identical
10 chemical moieties are at different orientations in space and, therefore, when pure, have the ability to rotate the plane of polarized light. However, some pure stereoisomers may have an optical rotation that is so slight that it is undetectable with present instrumentation.

"Optical isomerism" describes one type of stereoisomerism which
15 manifests itself by the rotation that the isomer, either pure or in solution, imparts to the plane of polarized light. It is caused in many instances by the attachment of four different chemical atoms or groups to at least one of the carbon atoms in a molecule. These isomers may be described as d-, l-, or a d,l-pair or D-, L- or a D,L-pair; or (R)-, (S)-,
20 or an (R,S)-pair, depending upon the nomenclature system employed.

The compounds of Formula I exist in two isomeric configurations defined by the relationship of the 10,11-methano and the 5-piperazinyl substituents on the dibenzosuberane (see, for example, the structure represented in Formula II, in the Nomenclature description which follows).
25 When the 10,11-methano and the 5-piperazinyl substituents are both oriented in the same direction vis-a-vis the dibenzosuberane (e.g., both up or both down) the isomeric form is called "syn." When the 10,11-methano and the 5-piperazinyl substituents are oriented in opposite directions vis-a-vis the dibenzosuberane (e.g., one up and the other down) the isomeric form is
30 called "anti."


Certain compounds of Formula I will have an asymmetric center within the group identified as "A" where R' or R'' is not hydrogen. These compounds can exist in two stereochemical forms, called (+) and (-) or called (R)- and (S)-, or as mixtures of the two stereoisomers. The (R)- and (S)-
35 designation will be used in this application.

While specific stereoisomers are disclosed and named, the present invention is to be interpreted to include the individual stereoisomers as well as mixtures, racemic and otherwise, thereof.

-7-

Nomenclature

The compounds of Formula I are named and numbered as described below with reference to Formula II.


**Formula II**

For example, the compound where R^1 and R^2 are chloro, R^3 is hydroxy, and the phenyl group (of R^3 in Formula 1) is substituted at the 3-position with NO_2 is named (3R,S)-anti,syn-1-{4-[4-(10,11-dichloromethanodibenzosuber-5-yl)piperazin-1-yl]-3-hydroxybutoxy}-3-nitrobenzene.

The compound where R^1 and R^2 are hydrogen, R^3 is acetoxy (in the isomeric form going down into the page), the phenyl group (of R^3 in Formula 1) is substituted at the 5-position with trifluoromethyl, and the bond connecting the 4-position of the piperazine to the 5-position of the benzosuberane is in the isomeric form going up from the page, is named (2S)-syn-1-{4-[4-(10,11-methanodibenzosuber-5-yl)piperazin-1-yl]-2-acetoxybutoxy}-5-trifluoromethylbenzene.

A preferred compound of the invention, illustrated below as Formula III:

- 8 -



Formula III

which is the compound of Formula I wherein R¹ and R² are F, A is (2R)-hydroxypropyl, and R³ is quinolyl attached at the 5-position to the oxygen, is named (2R)-anti-5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline. Alternatively, the Chemical Abstracts nomenclature for the compound of Formula III is 1-(4-anti(1,1-difluoro-1a,10b-dihydrodibenzo[a,e]cyclopropano[cyclohepten-6-yl)piperazin-1-yl)-(2R)-3-(5-quinolyloxy)-2-propanol (the numbering represented in Formula III does not apply for the Chemical Abstracts nomenclature system). While either nomenclature system adequately describes the compounds of the present invention, the former system will be employed for purposes of the present specification.

Synthetic Reaction Parameters

The terms "solvent", "inert organic solvent" or "inert solvent" mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like]. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents.

The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).

Unless specified to the contrary, the reactions described herein take

place at atmospheric pressure within a temperature range from 5°C to 100°C (preferably from 10°C to 50°C; most preferably at "room" or "ambient" temperature, e.g., 20°C). However, there are clearly some reactions where the temperature range used in the chemical reaction will be above or below these temperature ranges. Further, unless otherwise specified, the reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about 5°C to about 100°C (preferably from about 10°C to about 50°C; most preferably about 20°C) over a period of about 1 to about 10 hours (preferably about 5 hours). Parameters given in the Examples are intended to be specific, not approximate.

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can, of course, also be used.

Synthesis of the Compounds of Formula I

The compounds of Formula I can be prepared by following the procedures described in U.S. Patent No. 5,112,817, incorporated herein by reference, by substituting the dibenzosuberone with an optionally substituted 10,11-methanodibenzosuberone, prepared, for example, as described in Ciganek, et al., "Imine Analogues of Tricyclic Antidepressants," *J. Med. Chem.*, 1981, 24, 336-41; or in Coyne and Cusic, "Aminoalkyldibenzo[a,e]cyclopropa[c]cycloheptene Derivatives. A Series of Potent Antidepressants," *J. Med. Chem.*, 1974, Vol. 17, No. 1, 72-75, both incorporated herein by reference. Various syntheses of the compounds of Formula I are described below with reference to Reaction Schemes 1, 2 and 3.

A key role in the synthesis of the compounds of Formula I plays the 1-[10,11-methanodibenzosuber-5-yl]piperazine of Formula 4 below which may be optionally substituted in positions 10 and 11. This key intermediate is coupled or condensed with a reagent that comprises the group A-O-R' to afford, or to be converted into, the compounds of Formula I; or a reagent that comprises in essence the group A-epoxide or a derivative thereof, the group A'-O-R' to afford, or to be converted into, the compounds of Formula I. Such conversions include, e.g., the acylation of a hydroxy group present in group A' to an acyloxy group, or the removal of an acyloxy group in group A' or the conversion of the group A-epoxide with R'-OH to a compound of Formula I. In that conversion when R'-OH is added to the group A-epoxide, the epoxide ring is opened whereby a hydroxy group vicinal to

-10-

the carbon atom to which $-OR^3$ is attached is formed.

Brief Description Of Reaction Schemes

Reaction Scheme 1 illustrates synthesis of the compounds of Formula I where R^3 is H or OH.

Reaction Scheme 2 illustrates synthesis of the compounds of Formulae 8 and 9; these are employed as reactants in Step 5 of Reaction Scheme 1 as precursors in the synthesis of the compounds of Formula I.


Reaction Scheme 3 illustrates synthesis of the compounds of Formula I where R^3 is OH.

As used in the Reaction Schemes, the substituents A, R^1 , R^2 , R^3 , R^4 and R^5 have the same meaning as described in the Summary of the Invention. The substituent "X" indicates a halo group; n is 1 or 2; and m is 1, 2, 3 or 4.

Starting Materials

The compound 5H-dibenzo[a,d]cyclohepten-5-one (also named dibenzo[a,d]-5H-cyclohepten-5-one or dibenzosuberone) is commercially available, e.g., from Aldrich Chemical Company, Milwaukee, WI. Other reactants, such as epibromohydrin and 1-bromo-3,4-epoxybutane, are likewise commercially available or may be readily prepared by those skilled in the art using commonly employed synthetic methodology.


REACTION SCHEME 1



-11-

Formula 2


Step 3



Formula 3


Formula 3

Step 4




Formula 4

Formula 4




Formula 8

or



Formula 9

Step 5



Formula 1

Preparation of the Compounds of Formula 1

A solution of an acetate (such as sodium chlorodifluoro-acetate, methyl trichloroacetate, ethyl trifluoroacetate; depending upon the desired substituents for R^1 and R^2) in a solvent (such as diglyme, benzene, or petroleum ether) is added over a period of 4 to 8 hours (preferably 6 hours) to a solution of dibenzosuberone (for example in diglyme) with stirring and under nitrogen, maintaining the reaction temperature at 160-165°C. (Other reaction temperatures may be employed depending upon the

reactants used, as described in Ciganek, et al. and in Coyne and Cusic.) The reaction mixture is brought to room temperature, then poured into water and extracted (e.g., with ether). The desired 10,11-substituted-methanodibenzo-suberone is isolated and purified by conventional means, for example, the organic (e.g., benzene) phase is washed with water, dried (e.g., over Na_2SO_4), evaporated, and the residue is recrystallized (e.g., from ethanol, and optionally again, e.g., from acetone/hexane).

Alternatively, compounds of Formula 2 where R^1 and R^2 are not identical, such as H and Cl, respectively, can be prepared as described in *J. Med. Chem.*, Vol. 17, 72 (1974), incorporated herein by reference. The compound of Formula 2 where R^1 and R^2 are both hydrogen can be prepared as described in Coyne and Cusic, "Aminoalkyldibenzo[a,e]cyclopropano[c]cycloheptene Derivatives. A Series of Potent Antidepressants," *J. Med. Chem.*, 1974, Vol. 17, No. 1, 72-75, previously incorporated herein by reference.

Preparation of the Compounds of Formula 2

A solution of an 10,11-(optionally substituted)-methanodibenzosuberone in a solvent (e.g., THF/methanol) is cooled (e.g., in an ice bath) and a reducing agent (e.g., sodium borohydride) is added in portions. The reaction mixture is allowed to come to room temperature and stirred for 1 to 5 hours (preferably 2 hours), then poured into water. The product is isolated (e.g., by filtration) and purified by conventional means (e.g., washed with water and dried) to give the corresponding 10,11-(optionally substituted)-methanodibenzosuberol.

Preparation of the Compounds of Formula 3 Where R = Formyl

A solution of an 10,11-(optionally substituted)-methanodibenzosuberol in a solvent (e.g., dioxane) is cooled (e.g., in an ice bath) followed by halogenation [e.g., by dropwise addition of thionyl chloride, maintaining an elevated temperature (40 to 70 °C, preferably 50°C) for 2 to 5 hours (preferably 4 hours)]. The reaction mixture is evaporated to dryness, giving a mixture of syn- and anti- isomers of the corresponding 5-halo-10,11-(optionally substituted)-methanodibenzosuberane. This halogenated suberane is, without further purification, dissolved (e.g., in acetonitrile) and a piperazine is introduced by nucleophilic displacement of the halide [e.g., by adding 1-piperazinecarboxaldehyde with stirring, preferably under dry N_2 at elevated temperature (e.g., 100°C) for 10 to 30 hours (preferably 20 hours)]. The reaction mixture is evaporated to dryness and the desired 1-[10,11-(optionally substituted)-methanodibenzosuber-5-yl]-4-formylpiperazine product is isolated and purified by conventional means [e.g., the residue is partitioned between aqueous NaHCO_3 and ethyl acetate, the organic phase washed with water, dried (e.g., over K_2CO_3) and evaporated]. The individual syn- and anti- isomers are separated, e.g., by flash chromatography of the residue on silica gel

-13-


(30% acetone/hexane).

Preparation of the Compounds of Formula 4

A solution of a 1-[10,11-(optionally substituted)methano-
 5 dibenzosuber-5-yl]-4-formyl-piperazine and potassium hydroxide in a solvent
 (e.g., 9:1 ethanol/H₂O) is refluxed for 0.5 to 2 hours (preferably 1 hour),
 then cooled. The cooled reaction mixture is concentrated, diluted with
 water, extracted (e.g., with ethyl acetate), dried (e.g., over K₂CO₃), and
 10 the organic phase is evaporated to give the corresponding 1-[10,11-
 (optionally substituted)methanodibenzosuber-5-yl]piperazine.

Preparation of the Compounds of Formula I

A solution of a compound of Formula 8 (e.g., a 1-(aryloxy or
 15 heteroaryloxy)-2,3-epoxypropane or a 1-(aryloxy or heteroaryloxy)-3,4-
 epoxybutane) or an aryloxy- or heteroaryloxy-alkyl halide of Formula 9 and
 a 1-[10,11-(optionally substituted)methanodibenzosuber-5-yl]piperazine is
 refluxed in a solvent (e.g., isopropanol) for 10 to 30 hours (preferably 20
 hours). The desired product, a corresponding 10,11-methanodibenzosuberane
 20 derivative of Formula I, is isolated and purified by conventional means
 [for example, evaporated to dryness and chromatographed on silica gel
 (e.g., using 70:30:1 ethyl acetate/hexane/triethylamine)].

REACTION SCHEME 2**Preparation of the Compounds of Formula 8**

An aryl- or heteroaryl alcohol (such as benzofurazan-4-ol, quinolin-
 35 5-ol, or 2-nitrophenol), dissolved in a solvent (e.g., acetonitrile, THF,
 or dimethyl formamide) is treated with a slight excess of a strong base
 (e.g., sodium hydride or potassium t-butoxide). The mixture is heated
 (e.g., at 50°C) for 10 minutes to 2 hours (preferably 30 minutes). A
 40 compound of Formula 6 (such as 1-chloro-2,3-epoxybutane, 1-bromo-2,3-
 epoxybutane, epibromohydrin, epichlorohydrin, or a tosyl or mesyl
 derivative thereof) is added and the mixture is heated (e.g., at 60°C for 1
 to 5 hours; preferably 2 hours). The reaction mixture is poured into water
 and extracted (e.g., with ethyl acetate). The organic phase is washed with


water, dried over Na_2SO_4 , and evaporated to give the corresponding 1-(aryloxy or hetero-aryloxy)-2,3-epoxypropane or 1-(aryloxy or heteroaryloxy)-3,4-epoxybutane, which is isolated and purified by conventional means [e.g., chromatographed on silica gel (50% ethyl acetate/hexane)].

The compounds of Formula 8, such as 1-(5-quinolyloxy)-2,3-epoxypropane can also be synthesized as described in *Drug Design and Discovery*, Vol. 9, 69 (1992), incorporated herein by reference.


Preparation of the Compounds of Formula 9

As illustrated in Reaction Scheme 2, the anion of an aryl- or heteroaryl alcohol of Formula 5 is reacted with a dihaloalkyl compound of Formula 7, such as 1-bromo-2-chloroethane, 1-bromo-3-chloropropane or 1-bromo-4-chlorobutane, in a solvent (such as acetone, THF, or DMF) at a temperature ranging from room temperature to the boiling point of the solvent employed, to give the corresponding haloalkyloxyaryl (or heteroaryl) compound of Formula 9. This synthesis is described in U.S. Patent No. 5,112,817, previously incorporated herein by reference.

REACTION SCHEME 3



-15-



Preparation of the Compounds of Formula 10

As illustrated in Reaction Scheme 3, Step 1, a 1-[10,11-(optionally substituted)-methanodibenzosuber-5-yl]piperazine of Formula 4 is reacted with a compound of Formula 6 (e.g., the compound where n is 2 is illustrated in Reaction Scheme 3; other compounds of Formula 6 will give corresponding products) under the conditions described above in connection with the Preparation of Formula 8 (in Reaction Scheme 2), to give a 1-[10,11-(optionally substituted)-methanodibenzosuber-5-yl]-4-(3,4-epoxybutyl)piperazine compound of Formula 10.

Preparation of the Compounds of Formula I Where R^b is OH

As illustrated in Reaction Scheme 3, Step 2, a 1-[10,11-(optionally substituted)-methanodibenzosuber-5-yl]-4-(3,4-epoxybutyl)piperazine compound of Formula 10 is reacted with an aryl- or heteroaryl alcohol (such as benzofurazan-4-ol, quinolin-5-ol, or 2-nitrophenol), under the conditions described above in connection with the Preparation of Formula I (in Reaction Scheme 1), to give the corresponding compound of Formula I where R^b is OH.

Preparation of the Compounds of Formula I Where R^a or R^b is Lower Alkoxy

The compounds of Formula I where R^a or R^b is lower alkoxy are prepared as described in U.S. Patent No. 5,112,817, previously incorporated by reference, starting from the corresponding compound of Formula I where R^a or R^b is OH (prepared as described above). For example, a compound of Formula I where R^a or R^b is OH is reacted with an acyl chloride to generate the corresponding alkoxy compound.

Preparation of the Salts of the Compounds of Formula I

The compounds of Formula I can be converted to corresponding acid addition salts. The conversion is accomplished by treatment with a stoichiometric amount of an appropriate acid, such as hydrochloric acid (e.g., 3 molar equivalents to form the trihydrochloride salt in case the compound of Formula I includes three basic nitrogen atoms). If R¹ is phenyl the compound of Formula I has only two basic nitrogens and will only absorb two equivalents of acid to form the acid addition salt. If the substituent R¹ includes two basic nitrogen atoms, the base of Formula I will absorb four equivalents of acid. The preferred acid addition salts of the invention will include 2 or 3 equivalents of acid. Most preferred are acid addition salts with three equivalents of acid. In the salt-forming step of this invention typically, the free base is dissolved in a polar organic solvent, such as methanol or ethanol, and the acid is added in water, methanol or ethanol. The temperature is maintained at 0°C to 50 °C. The corresponding salt precipitates spontaneously or can be brought out of solution with a less polar solvent, or by evaporation of the solvent or by cooling the solution.

In the step of liberating the free base of Formula I according to the invention the acid addition salts of the compounds of Formula I can be decomposed to the corresponding free bases by treatment with an excess of a suitable base, such as ammonia or sodium bicarbonate, typically in the presence of an aqueous solvent, and at a temperature between 0°C and 50°C. The free base is isolated by conventional means, such as extraction with an organic solvent. It is self-evident that the stoichiometric excess must take into account the number of equivalents of acid bound by the base of Formula I.

The preferred free bases of Formula I include 2 or 3 basic nitrogen atoms. Bases with 3 basic nitrogen atoms are most preferred.

Preferred Processes and Last Steps

A 1-(aryloxy or heteroaryloxy)-2,3-epoxypropane or a 1-(aryloxy or heteroaryloxy)-3,4-epoxybutane, or an aryloxy- or heteroaryloxyalkyl halide, and a 1-[10,11-(optionally substituted)methanodibenzosuber-5-yl]piperazine are combined to give the corresponding 10,11-methanodibenzosuberane derivative of Formula I.

A compound of Formula I where R¹ or R² is OH is reacted with an acyl chloride to generate the corresponding acyloxy compound.

A compound of Formula I where R¹ or R² is OH is reacted with the alcohol R³-OH to give the corresponding 10,11-methanodibenzosuberane derivative of Formula I.

A compound of Formula I is contacted with a pharmaceutically acceptable acid to form the corresponding acid addition salt.

A pharmaceutically acceptable acid addition salt of Formula I is contacted with a base to form the corresponding free base of Formula I.

Preferred Compounds

Preferred are the compounds of Formula 1 where R¹ and R² are fluoro. Also preferred are those compounds where A is 2-hydroxypropylene. Also preferred are those compounds where R³ is 5-quinolyl or 4-benzofurazyl. Further preferred are those compounds which combine the above-mentioned features. Certain single isomers are also preferred.

Most preferred is the compound 5-{3-[4-(10,11-difluoro-methanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}-quinoline; particularly the (2R)-anti isomer thereof.

Utility, Testing and Administration

General Utility

The compounds of the present invention are chemosensitizing or potentiating agents, and are also useful as resistance modifying agents. They are useful for treating multidrug resistance (i.e., after clinical resistance becomes evident), and can also be administered at the time of initial chemotherapy (i.e., before any clinical resistance becomes evident) to enhance the activity of anticancer agents when first administered. The compounds of the present invention are also useful for the treatment of drug-resistant malaria.

Testing

In vitro activity for chemosensitizing or potentiating agents, particularly for treating multidrug resistance, is determined by an MTT Proliferation Assay, for example a modification of the assay described in Mosmann, T. "Rapid Colorimetric Assay For Cellular Growth And Survival: Application to proliferation and cytotoxicity assays," *J. Immunol. Meth.*, Vol. 65, 55-63 (1983). Another MTT Proliferation Assay is described in Alley, et al., "Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay," *Cancer Research*, Vol. 48, 589-601 (1988).

In vivo activity for chemosensitizing or potentiating agents, particularly for treating multidrug resistance, is determined, for example, as described in Slate and Michelson, "Drug Resistance Reversal Strategies: A Comparison Of Experimental Data With Model Predictions," *J. Natl. Cancer Inst.*, Vol. 83, 1574-1580 (1991). Other in vivo testing procedures are described in Sato, et al., "Circumvention of Multidrug Resistance by a Newly Synthesized Quinoline Derivative, MS-073," *Cancer Research*, Vol. 51, 2420-2424 (1991); Tsuruo, et al., "Circumvention of Vincristine and Adriamycin Resistance in Vitro and in Vivo by Calcium Influx Blockers,"

Cancer Research, Vol. 43, 2905-2910 (1983); and Tsuruo, et al., "Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil," *Cancer Research*, Vol. 41, 1967-1972 (1981).

5 Aqueous stability of the compounds is determined by conventional procedures, e.g., by measuring the amount of a compound remaining in solution at various pH values and temperatures.

Administration

10 The compounds of Formula 1 are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described, typically by co-administration with a second active agent, preferably a cancer chemotherapeutic agent, particularly selected from the group of agents listed above, and most
15 preferably, a cancer chemotherapeutic agent to which clinical resistance has become evident in the mammal being treated. Administration of the compounds of the invention or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities.

20 While human dosage levels have yet to be optimized for the compounds of the invention, generally, a daily dose is from about 0.01 to 4.0 mg/kg of body weight, preferably about 0.1 to 2.0 mg/kg of body weight, and most preferably about 0.3 to 1.0 mg/kg of body weight. Thus, for administration to a 70 kg person, the dosage range would be about 0.7 to 280 mg per day,
25 preferably about 7.0 to 140 mg per day, and most preferably about 21 to 70 mg per day. The amount of active compound administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration (e.g., oral administration one day prior to cancer chemotherapy and intravenous
30 administration during cancer chemotherapy) and the judgment of the prescribing physician.

 In employing the compounds of this invention for treatment of the above conditions, any pharmaceutically acceptable mode of administration can be used. The compounds of Formula I can be administered either alone
35 or in combination with other pharmaceutically acceptable excipients, including solid, semi-solid, liquid or aerosol dosage forms, such as, for example, tablets, capsules, powders, liquids, suspensions, suppositories, aerosols or the like. The compounds of Formula I can also be administered in sustained or controlled release dosage forms, including depot
40 injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for the prolonged administration of the compound at a predetermined rate, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions will typically include a conventional pharmaceutical carrier or excipient and a compound of
45 Formula I or a pharmaceutically acceptable salt thereof. In addition,

these compositions may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc., such as the cancer chemotherapeutic agents listed above.

Generally, depending on the intended mode of administration, the pharmaceutically acceptable composition will contain about 0.1% to 90%, preferably about 0.5% to 50%, by weight of a compound or salt of Formula I, the remainder being suitable pharmaceutical excipients, carriers, etc.

One preferred manner of administration for the conditions detailed above is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of affliction. For such oral administration, a pharmaceutically acceptable, non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like. Such compositions include solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations and the like.

Preferably the compositions will take the form of a pill or tablet. Thus the composition will contain along with the active ingredient: a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, gelatin, polyvinylpyrrolidone, cellulose and derivatives thereof, and the like.

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound in an amount sufficient to alleviate the symptoms of the subject being treated.

Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier may be prepared.

For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed

excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum and the like. Such compositions take the form of solutions, suspensions, tablets, capsules, powders, sustained release formulations and the like. Such compositions may contain 0.01%-95% active ingredient, preferably 0.1-50%.

For a solid dosage form, the solution or suspension, in for example propylene or ethylene carbonate or mixtures thereof, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule. Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Patents Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g. in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.

Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycol, triglycerides, propylene glycol esters (e.g. propylene carbonate), ethylene carbonate and mixtures thereof and the like, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.

Other useful formulations include those set forth in U.S. Patents Nos. Re. 28,819 and 4,358,603.

Suitability for oral and parenteral administration is another advantage of the present invention, due to the superior stability characteristics that have been found for compounds of Formula I, a problem identified with MS-073.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, solubility enhancers, and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, cyclodextrins, etc.

A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795.

The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are

-21-

employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably the composition will comprise 0.2-2% of the active agent in solution.

Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients can also be administered.

Formulations of the active compound or a salt may also be administered to the respiratory tract as an aerosol or solution from a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation have diameters of less than 50 microns, preferably less than 10 microns.

EXAMPLES

The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

EXAMPLE 1

10,11-Difluoromethanodibenzosuberone

1A. Formula 1 where R¹ and R² are F

A solution of sodium chlorodifluoroacetate (350 g) in diglyme (1400 ml) was added dropwise during 6 hours to a solution of dibenzosuberone (25 g) in diglyme (500 ml), with overhead stirring and under nitrogen, maintaining the reaction temperature at 160-165°C. The cooled reaction mixture was poured into water (1.8 l) and extracted with ether (1.8 l). The organic phase was washed with water, dried over Na₂SO₄, and evaporated. The residue was recrystallized from ethanol, then from acetone/hexane to give 14 g of 10,11-difluoromethanodibenzosuberone, mp 149.6°C. Flash chromatography of the combined mother liquors on silica gel, eluting with 20% acetone/hexane, gave an additional 6.5 g of the desired material.

1B. Formula 1 varying R¹ and R²

By following the procedure of part A, and substituting sodium chlorodifluoroacetate with the following:

- a. methyl trichloroacetate,
- b. methyl tribromoacetate, and
- c. sodium dichlorofluoroacetate;

there are obtained the following respective compounds:

- a. 10,11-dichloromethanodibenzosuberone,
- b. 10,11-dibromomethanodibenzosuberone, and

- c. 10,11-chlorofluoromethanodibenzosuberone;

EXAMPLE 2

10,11-Difluoromethanodibenzosuberol

5

- 2A. Formula 3 where R¹ and R² are F

A solution of 10,11-difluoromethanodibenzosuberone (20.4 g) in THF/MeOH (1:2, 900 ml) was cooled in an ice bath. Sodium borohydride (12 g) was added in portions. The cooling bath was removed, the reaction mixture was stirred at ambient temperature for 2 hours, and poured into water. The product was filtered off, washed with water, and dried to give 20 g of 10,11-difluoromethanodibenzosuberol, mp 230.1-230.6°C.

10

- 2B. Formula 2 varying R¹ and R²

15

By following the procedure of part A, and substituting 10,11-difluoromethanodibenzosuberone with the following:

a.

10,11-dichloromethanodibenzosuberone,

b. 10,11-dibromomethanodibenzosuberone,

c. 10,11-methanodibenzosuberone, and

20

d. 10,11-chlorofluoromethanodibenzosuberone;

there are obtained the following respective compounds:

a. 10,11-dichloromethanodibenzosuberol,

b. 10,11-dibromomethanodibenzosuberol,

c. 10,11-methanodibenzosuberol, and

25

d. 10,11-chlorofluoromethanodibenzosuberol.

EXAMPLE 3

Syn- and Anti-

1-(10,11-Difluoromethanodibenzosuber-5-yl)-4-formylpiperazine

30

- 3A. Formula 3 where R¹ and R² are F, and R is Formyl

35

To a solution of 10,11-difluoromethanodibenzosuberol (5.2 g) in dioxane (70 ml), cooled in an ice bath, was added thionyl chloride (4.5 ml) dropwise. The temperature was raised to 50°C and maintained for four hours. The reaction mixture was evaporated to dryness, giving a mixture of syn- and anti-5-chloro-10,11-difluoromethanodibenzosuberane (5.7 g), which was dissolved in acetonitrile (200 ml) and 1-piperazinecarboxaldehyde (10 ml) was added. The mixture was stirred under dry N₂ at 100°C (bath temperature) for 20 hours and then evaporated to dryness. The residue was partitioned between aqueous NaHCO₃ and ethyl acetate. The organic phase was washed with water, dried over K₂CO₃, and evaporated. Flash chromatography of the residue on silica gel (30% acetone/hexane) gave syn-1-(10,11-difluoromethanodibenzosuber-5-yl)-4-formyl-piperazine (2.4 g), mp 213°C., and anti-1-(10,11-difluoro-methanodibenzosuber-5-yl)-4-

40

-23-

formylpiperazine (2.6 g), mp 238°C.

3B. Formula 3 varying R¹ and R²

By following the procedure of part A, and substituting

10,11-difluoromethanodibenzosuberol with the following:

- a. 10,11-dichloromethanodibenzosuberol,
- b. 10,11-dibromomethanodibenzosuberol,
- c. 10,11-methanodibenzosuberol, and
- d. 10,11-chlorofluoromethanodibenzosuberol;

there are obtained the following respective compounds:

- a1. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)-4-formylpiperazine,
mp 205°C,
- a2. syn-1-(10,11-dichloromethanodibenzosuber-5-yl)-4-formylpiperazine,
- b1. anti-1-(10,11-dibromomethanodibenzosuber-5-yl)-4-formylpiperazine,
- b2. syn-1-(10,11-dibromomethanodibenzosuber-5-yl)-4-formylpiperazine,
- c1. anti-1-(10,11-methanodibenzosuber-5-yl)-4-formylpiperazine, mp 195°C,
- c2. syn-1-(10,11-methanodibenzosuber-5-yl)-4-formylpiperazine,
- d1. anti-1-(10,11-chlorofluoromethanodibenzosuber-5-yl)-
4-formylpiperazine, and
- d2. syn-1-(10,11-chlorofluoromethanodibenzosuber-5-yl)-
4-formylpiperazine.

EXAMPLE 4

Anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine

4A. Formula 4 where R¹ and R² are F

A solution of anti-1-(10,11-difluoromethanodibenzosuber-5-yl)-4-formylpiperazine (2.55 g) and potassium hydroxide (3.0 g) in ethanol/H₂O (9:1, 100 ml) was refluxed for 1 hour, then cooled. The cooled reaction mixture was concentrated, diluted with water, extracted with ethyl acetate and dried over K₂CO₃. The dried organic phase was evaporated to give anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine (2.35 g), mp 131°C.

4B. Formula 4 varying R¹ and R²

By following the procedure of part A, and substituting anti-1-(10,11-difluoromethanodibenzosuber-5-yl)-4-formylpiperazine with the following:

- a. syn-1-(10,11-difluoromethanodibenzosuber-5-yl)-4-formylpiperazine,
- b. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)-4-formylpiperazine,
- c. syn-1-(10,11-dichloromethanodibenzosuber-5-yl)-4-formylpiperazine,
- d. anti-1-(10,11-dibromomethanodibenzosuber-5-yl)-4-formylpiperazine,
- e. syn-1-(10,11-dibromomethanodibenzosuber-5-yl)-4-formylpiperazine,
- f. anti-1-(10,11-methanodibenzosuber-5-yl)-4-formylpiperazine,
- g. syn-1-(10,11-methanodibenzosuber-5-yl)-4-formylpiperazine,
- h. anti-1-(10,11-chlorofluoromethanodibenzosuber-5-yl)-

-24-

4-formylpiperazine, and

- i. syn-1-(10,11-chlorofluoromethanodibenzosuber-5-yl)-
4-formylpiperazine;

there are obtained the following respective compounds:

- 5 a. syn-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine, mp 225.5°C,
b. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)piperazine, mp 199°C,
c. syn-1-(10,11-dichloromethanodibenzosuber-5-yl)piperazine,
d. anti-1-(10,11-dibromomethanodibenzosuber-5-yl)piperazine,
e. syn-1-(10,11-dibromomethanodibenzosuber-5-yl)piperazine,
10 f. anti-1-(10,11-methanodibenzosuber-5-yl)piperazine, mp 103°C,
g. syn-1-(10,11-methanodibenzosuber-5-yl)piperazine,
h. anti-1-(10,11-chlorofluoromethanodibenzosuber-5-yl)piperazine, and
i. syn-1-(10,11-chlorofluoromethanodibenzosuber-5-yl)piperazine.

15

EXAMPLE 5

1-(4-Benzofurazanyloxy)-2,3-epoxypropane

5A. Formula 8 where R' is Benzofurazanyl and n is 1

Sodium hydride (620 mg; 60% oil dispersion) was added in portions to
20 benzofurazan-4-ol (1.74g) in dimethyl formamide
(30 ml). The mixture was heated at 50°C for 30 min. Epibromohydrin (1.6
ml) was added and the mixture was heated at 60°C for 2 hours. The reaction
mixture was poured into water and extracted with ethyl acetate. The
organic phase was washed with water, dried over Na₂SO₄, and evaporated. The
25 residue was chromatographed on silica gel (50% ethyl acetate/hexane) to
give 1-(4-benzofurazanyloxy)-2,3-epoxypropane (1.6 g), mp 75°C.

5B. Formula 8 varying R' and n

By following the procedure of part A, and substituting benzofurazan-
30 4-ol and epibromohydrin with the following:

- a. quinolin-5-ol and 1-chloro-3,4-epoxybutane,
b. 2-nitrophenol and epibromohydrin,
c. 2-chlorophenol and epibromohydrin,
d. 2-difluoromethoxyphenol and epibromohydrin,
35 e. pyridin-3-ol and epibromohydrin, and
f. quinolin-5-ol and epibromohydrin;

there are obtained the following respective compounds:

- a. 1-(5-quinolyloxy)-3,4-epoxybutane,
b. 1-(2-nitrophenoxy)-2,3-epoxypropane,
40 c. 1-(2-chlorophenoxy)-2,3-epoxypropane,
d. 1-(2-difluoromethoxyphenoxy)-2,3-epoxypropane,
e. 1-(3-pyridyloxy)-2,3-epoxypropane, and
f. 1-(5-quinolyloxy)-2,3-epoxypropane.

-25-

5C. Formula 9 varying R¹ and n

By following the procedure of part A and substituting benzofurazan-4-ol and epibromohydrin with the following:

- a. quinolin-5-ol and 1-bromo-3-chloropropane,
- b. quinolin-5-ol and 1-bromo-4-chlorobutane,
- c. 2-nitrophenol and 1-bromo-3-chloropropane;

there are obtained the following respective compounds:

- a. 1-(5-quinolyloxy)-3-chloropropane,
- b. 1-(5-quinolyloxy)-4-chlorobutane, and
- c. 1-(2-nitrophenoxy)-3-chloropropane.

EXAMPLE 6

(2R,S)-Anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline

6A. Formula I where R¹ and R² are F, A is (2R,S)-Hydroxypropyl, and R³ is 5-Quinoly

A solution of 1-(5-quinolyloxy)-2,3-epoxypropane (586 mg) and anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine (950 mg) in isopropanol (20 ml) was refluxed for 20 hours. The reaction mixture was evaporated to dryness and the residue was chromatographed on silica gel (70:30:1 ethyl acetate/hexane/ triethylamine) to give (2R,S)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazine-1-yl]-2-hydroxypropoxy}-quinoline (1.33 g), which was converted to the trihydrochloride salt, mp 193.5°C, by reaction with 3 molar equivalents of HCl.

6B. Formula I Isomers varying R¹, R², R³ and A

By following the procedure of part A, and substituting anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-2,3-epoxypropane with the following:

- a. syn-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-2,3-epoxypropane,
- b. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and (2R)-1-(5-quinolyloxy)-2,3-epoxypropane,
- c. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and (2S)-1-(5-quinolyloxy)-2,3-epoxypropane,
- d. syn-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and (2R)-1-(5-quinolyloxy)-2,3-epoxypropane,
- e. syn-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and (2S)-1-(5-quinolyloxy)-2,3-epoxypropane,
- f. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-2,3-epoxypropane,
- g. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)piperazine and (2R)-1-(5-quinolyloxy)-2,3-epoxypropane,

- h. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)piperazine and (2S)-1-(5-quinolyloxy)-2,3-epoxypropane,
- i. anti-1-(10,11-methanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-2,3-epoxypropane,
- 5 j. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(4-benzofurazanyloxy)-2,3-epoxypropane,
- k. syn-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(4-benzofurazanyloxy)-2,3-epoxypropane,
- 10 l. anti-1-(10,11-dichloromethanodibenzosuber-5-yl)piperazine and 1-(4-benzofurazanyloxy)-2,3-epoxypropane,
- m. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(2-nitrophenoxy)-2,3-epoxypropane,
- n. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(2-chlorophenoxy)-2,3-epoxypropane,
- 15 o. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(2-difluoromethoxyphenoxy)-2,3-epoxypropane,
- p. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(3-pyridyloxy)-2,3-epoxypropane,
- 20 q. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-3-chloropropane,
- r. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-4-chlorobutane,
- s. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(2-nitrophenoxy)-3-chloropropane, and
- 25 t. anti-1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine and 1-(5-quinolyloxy)-3,4-epoxybutane,

there are obtained the following respective compounds:

- a. (2R,S)-syn-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 208°C (trihydrochloride),
- 30 b. (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 190°C (trihydrochloride),
- c. (2S)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 195°C (trihydrochloride),
- d. (2R)-syn-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 193°C (trihydrochloride),
- 35 e. (2S)-syn-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 188.5°C (trihydrochloride),
- f. (2R,S)-anti-5-{3-[4-(10,11-dichloromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 195°C (trihydrochloride),
- 40 g. (2R)-anti-5-{3-[4-(10,11-dichloromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 218°C (trihydrochloride),
- h. (2S)-anti-5-{3-[4-(10,11-dichloromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline, mp 215°C (trihydrochloride),
- 45 i. (2R,S)-anti-5-{3-[4-(10,11-methanodibenzosuber-5-yl)piperazin-1-yl]-

-27-

2-hydroxypropoxy}quinoline, melting range 87.4 - 99.3°C; MS:
molecular ion = 491,

- j. (2R,S)-anti-4-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-2-hydroxypropoxy}benzofurazan, mp 186°C
(dihydrochloride),
- k. (2R,S)-syn-4-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-
1-yl]-2-hydroxypropoxy}benzofurazan, mp 188°C
(dihydrochloride),
- l. (2R,S)-anti-4-{3-[4-(10,11-dichloromethanodibenzosuber-
5-yl)piperazin-1-yl]-2-hydroxypropoxy}benzofurazan,
- m. (2R,S)-anti-1-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-2-hydroxypropoxy}-2-nitrobenzene,
- n. (2R,S)-anti-1-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-2-hydroxypropoxy}-2-chlorobenzene,
- o. (2R,S)-anti-1-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-2-hydroxypropoxy}-
2-difluoromethoxybenzene,
- p. (2R,S)-anti-3-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-2-hydroxypropoxy}pyridine,
- q. (2R,S)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-propoxy}quinoline,
- r. (2R,S)-anti-5-{4-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-butoxy}quinoline,
- s. (2R,S)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-propoxy}-2-nitrobenzene, and
- t. (2R,S)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-
5-yl)piperazin-1-yl]-3-hydroxybutoxy}quinoline.

EXAMPLE 7

This example illustrates the preparation of a representative
pharmaceutical formulation for oral administration containing an active
compound of Formula I, e.g., (2R)-anti-5-{3-[4-(10,11-
difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxy-
propoxy}quinoline.

Ingredients	Quantity per Tablet, mgs.
Active compound	200
lactose, spray-dried	148
magnesium stearate	2

The above ingredients are mixed and introduced into a hard-shell
gelatin capsule. If the trihydrochloride salt is used 243 mgs. of salt are
being employed.

Other compounds of Formula I, such as those prepared in accordance
with the procedures described Examples 1-6, can be used as the active

-28-

compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 8

This example illustrates the preparation of another representative pharmaceutical formulation for oral administration, containing an active compound of Formula I, e.g., (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)-piperazin-1-yl]-2-hydroxypropoxy}quinoline.

<u>Ingredients</u>	<u>Quantity per tablet, mgs.</u>
Active compound	400
cornstarch	50
lactose	145
magnesium stearate	5

The above ingredients are mixed intimately and pressed into single scored tablets. If the trihydrochloride salt is used 486 mgs. of salt are being employed.

Other compounds of Formula I, such as those prepared in accordance with the procedures described in Examples 1-6, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 9

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline.

A suspension for oral administration is prepared having the following composition:

<u>Ingredients</u>	<u>Amount</u>
Active compound	1.0 g
fumaric acid	0.5 g
sodium chloride	2.0 g
methyl paraben	0.1 g
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
flavoring	0.035 ml
colorings	0.5 mg
distilled water	q.s. to 100 ml

-29-

If the trihydrochloride is used to obtain a suspension, 1.215 g of salt are being employed. Other compounds of Formula I, such as those prepared in accordance with Examples 1-6, can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 10

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline.

An injectable preparation buffered to a pH of 4 is prepared having the following composition:

<u>Ingredients</u>	<u>Amount</u>
Active compound	0.2 g
Sodium Acetate Buffer Solution (0.4 M)	2.0 ml
HCl (1N)	q.s. to pH 4
water (distilled, sterile)	q.s. to 20 ml

If the trihydrochloride salt is used to prepare the injectable preparation, .243 g of salt is being employed. Other compounds of Formula I, such as those prepared in accordance with Examples 1-6, can be used as the active compound in the preparation of the injectable formulations of this example.

EXAMPLE 11

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline.

A suppository totalling 2.5 grams is prepared having the following composition:

Active compound	500 mg
witepsol H-15*	balance

(*triglycerides of saturated vegetable fatty acid; a product of Riches-Nelson, Inc., New York, N.Y.).

If the trihydrochloride salt is used, 607 mgs. are being employed. Other compounds of Formula I, such as those prepared in accordance with Examples 1-6, can be used as the active compound in the preparation of the suppository formulations of this example.

EXAMPLE 12

Determination of Stability at Acid pH

Test compounds (15 µg) were dissolved in 3 ml of 0.01 N HCl (pH 2) and incubated at 37°C. At various times, 10 µl aliquots were withdrawn and injected into a 3 µm Pecosphere C-18 cartridge column (3.3 x 0.46 cm) for HPLC analysis (mobile phase: 35% acetonitrile/18% tetrahydrofuran/47% potassium phosphate monobasic, containing 4 mM N,N-dimethyloctylamine; flow rate 1.0 ml/min). The test compounds and their degradation products were monitored by UV absorption at 240 nm. Disappearance of the parent compound was expressed as a percent peak height relative to time zero, from which $t_{1/2}$ values were determined graphically, as follows.

MS-073 (US 5,112,817), $t_{1/2}$ = 15 minutes,

(2R,S)-anti-5-{3-[4-(10,11-methanodibenzosuber-5-yl)piperazine-1-yl]-2-hydroxypropoxy}quinoline, $t_{1/2}$ = 2.5 hours,

(2R,S)-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazine-1-yl]-2-hydroxypropoxy}quinoline, $t_{1/2}$ = >72 hours, and

(2R,S)-anti-5-{3-[4-(10,11-chloromethanodibenzosuber-5-yl)piperazine-1-yl]-2-hydroxypropoxy}quinoline, $t_{1/2}$ = >72 hours.

The compounds of the present invention exhibit significant stability at acid pH, improved over MS-073, when tested by this method.

EXAMPLE 13

Determination of Activity in Vitro

Utilizing the MTT Assay

This is a modification of the assay described by Mosmann, T. in "Rapid Colorimetric Assay For Cellular Growth And Survival: Application to proliferation and cytotoxicity assays," *J. Immunol. Meth.*, Vol. 65, 55-63 (1983).

Cell stock (0.3 ml) containing multidrug resistant CH³CS Chinese hamster cells (about 2 x 10⁵ cells/ml) is combined with medium (2.7 ml) containing the compound to be tested or a vehicle control, in the presence or absence of adriamycin (1 µg/ml) to form a suspension. Aliquots (0.1 ml) of the cell suspension are then plated into eight wells in each of three 96-well microtiter plates. After incubation in a tissue culture incubator at 37°C, one plate is removed at each of the following time points: 24 hours, 48 hours and 72 hours. Upon removal from the incubator, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, MTT (10 µl, from a stock solution of 5 mg/ml in phosphate buffered saline) is added to each well of the plate, which is then returned to the incubator for three hours.

The formazan crystals generated by the activity of mitochondrial enzymes in living cells are solubilized by aspirating off the medium and adding DMSO (150 µl/well) with mixing performed on an orbital shaker. A570

-31-

(reference wavelength 650 nm) is read on a Molecular Devices microplate reader, and results are expressed as a percentage of vehicle control or adriamycin control each day or as a graph of A570 over time.

The compounds of the present invention show activity when tested by this method. Specifically, the compound (2R)-anti-5-(3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy)-quinoline is more than 3 times more active than MS-73; the corresponding (2S)-anti isomer is about 1.7 times more active than MS-73 and the (2R,S)-anti mixture is about 1.6 times more active than MS-73.

EXAMPLE 14

Determination of Activity in Vivo Utilizing the MDR Assay

This is a modification of the assay described by Slate and Michelson, in "Drug Resistance Reversal Strategies: A Comparison Of Experimental Data With Model Predictions," J. Natl. Cancer Inst., Vol. 83, 1574-1580 (1991).

Mice (B6D2F1, female, 7-8 weeks, approx. 20 gm, Jackson Laboratory) are randomized, weighed, and divided into groups of 6-7 each. On day 0 each mouse is injected ip with 0.2 ml of P388/ADR multidrug resistant murine leukemia cells, 2.4×10^7 cells/ml. Two hours later, each mouse is implanted ip with an Alzet 7-day minipump (Model 2001, Alza Corporation, Palo Alto, CA) containing the vehicle (DMSO/PBS) plus adriamycin (3 mg/kg/day), a test compound alone (30 mg/kg/day) or adriamycin (3 mg/kg/day) plus a test compound (at 0.3, 3, 10 and 30 mg/kg/day). The mice are monitored daily and deaths recorded starting on day 7. Survival time increased over the vehicle control and adriamycin groups indicates activity.

The compounds of the present invention show activity when tested by this method. Specifically, the compound (2R)-anti-5-(3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy)quinoline is more than 4 times more active than MS-73; and the corresponding (2S)-anti isomer is about 1.3 times more active than MS-73.

Furthermore, in the human uterine sarcoma assay the compound (2R)-anti-5-(3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy)quinoline is 3 times more active than MS-73.

EXAMPLE 15

Toxicity of the Compounds of Formula I

Mice received (2R)-anti-5-(3-[4-(10,11-difluoromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy)quinoline intravenously as a bolus injection once daily for up to two weeks at dosages of 0 (vehicle: 5% w/v mannitol in purified water), 10, 30 and 100 mg/kg. All mice in the 0-, 10- and 30-mg/kg groups survived. All mice given 100 mg/kg exhibited clonic


-32-

convulsions and died after the first dose. The cause of death was not determined.

-33-

WHAT IS CLAIMED IS:

1. A compound represented by the formula:



wherein:

A is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CHR}^a-\text{CH}_2-$, or $-\text{CH}_2-\text{CHR}^a-\text{CHR}^b-\text{CH}_2-$, where one of R^a or R^b is H, OH, lower alkoxy, and the other is H;

R^1 is H, F, Cl or Br;

R^2 is H, F, Cl or Br; and

R^3 is heteroaryl or optionally substituted phenyl where the substituents are selected from F, Cl, Br, CF_3 , CN, NO_2 and OCHF_3 ; or a pharmaceutically acceptable salt thereof.


2. The compound or salt of Claim 1 wherein R^3 is quinolyl or benzofurazanyl or phenyl optionally substituted with F, Cl, Br, CF_3 , CN, NO_2 or OCHF_3 .

3. The compound or salt of Claim 1 or 2 wherein R^a or R^b is OH.

4. The compound or salt of Claim 3 wherein A is $-\text{CH}_2-\text{CHR}^a-\text{CH}_2-$, and R^a is OH.


5. The compound of Claim 1 having the formula:

-34-



or a pharmaceutically acceptable salt thereof.


6. The compound of Claim 1 having the formula:



or a pharmaceutically acceptable salt thereof.

-35-

7. The compound of Claim 1 having the formula:



or a pharmaceutically acceptable salt thereof.

8. A method of treatment for multidrug resistance comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt according to Claim 1 to 7.

9. A method of reversing multidrug resistance comprising co-administering to a mammal evidencing clinical resistance to a cancer chemotherapeutic agent, a resistance modifying amount of a compound or salt of Claim 1 to 7 and a therapeutically effective amount of said cancer chemotherapeutic agent.

10. A method of treatment comprising administering to a mammal in need thereof a compound or salt according to Claim 1 to 7 in an amount therapeutically effective to potentiate the efficacy of a co-administered cancer chemotherapeutic agent.

-36-

11. A method of treatment for drug-resistant malaria comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt according to Claim 1 to 7.

12. A chemosensitizing method for enhancing bioavailability of a pharmaceutically active agent comprising administering to a mammal in need thereof an amount of a compound or salt of Claim 1 to 7 sufficient to increase permeation of an active agent through the blood-brain barrier.

13. A chemosensitizing method for enhancing bioavailability of a pharmaceutically active agent comprising administering to a mammal in need thereof an amount of a compound or salt of Claim 1 to 7 sufficient to increase permeation of an active agent through the gastrointestinal tract.


14. A pharmaceutical composition comprising a compound or salt according to Claim 1 to 7.

15. The composition of Claim 14 which includes a pharmaceutically acceptable excipient.

16. The use of a compound or a salt according to Claim 1 to 7 in the preparation of a pharmaceutical composition.

17. A compound or a salt according to Claim 1 to 7 as chemosensitizer.

18. A process for preparing a compound represented by the formula:



wherein:

A is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CHR}^a-\text{CH}_2-$, or $-\text{CH}_2-\text{CHR}^a-\text{CHR}^b-\text{CH}_2-$, where one of R^a or R^b is H, OH, lower alkoxy, and the other is H;

-37-

R^1 is H, F, Cl or Br;


R^2 is H, F, Cl or Br; and

R^3 is heteroaryl or optionally substituted phenyl where the


substituents are selected from F, Cl, Br, CF_3 , CN, NO_2 and $OCHF_3$;
or a pharmaceutically acceptable salt thereof; which process comprises

(a) condensation of a compound of Formula 4 with a compound of Formula 8 or 9 to afford a compound of Formula I or its pharmaceutically acceptable salt according to the following reaction schedule wherein:

A, R^1 , R^2 , R^3 , m and n have the above meanings and X is halogen:



(b) condensation of an epoxide of Formula 10 with a compound of Formula R^3 -OH to afford a compound of Formula I or its pharmaceutically acceptable salt according to the following reaction schedule



-38-

wherein:

R¹, R², and R³ have the above meanings;

(c) reaction of a compound of Formula I wherein R¹ or R² is OH with a lower acyl halide of the Formula R¹-C(O)-X, wherein R¹ is lower alkyl and X is halogen to afford a compound of Formula I wherein:

R¹, R² and R³ have the above meanings and R¹ or R² is lower acyloxy;

(d) contact of a compound of Formula I with a pharmaceutically acceptable acid to form the corresponding acid addition salt; or

(e) contact of an acid addition salt of a compound of Formula I with a base to form the corresponding free base of Formula I.

19. The process of Claim 18 wherein 1-(5-quinolyloxy)-2,3-epoxypropane is condensed with 1-(10,11-difluoromethanodibenzosuber-5-yl)piperazine to afford 5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline.

20. The process of Claim 19 wherein 5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline is isolated as the (2R)-anti isomer.

INTERNATIONAL SEARCH REPORT

Int. Appl. No.
PCT/US 94/04215

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D215/20 C07D213/65 C07D271/12 C07D295/08 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,3 133 925 (JOHN W. CUSIC) 19 May 1964 *Document*	1-20
A	EP,A,0 229 623 (HOECHST) 22 July 1987 *Page 35: example 15* *Page 39* *Page 54-62: claims*	1-17
A	FR,A,2 112 509 (PFIZER CORPORATION) 5 November 1971	1-20
A	FR,A,2 567 885 (SANDOZ) 24 January 1986 *Page 32: example 51-53* *Page 51-58: claims*	1-17
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

3 August 1994

Date of mailing of the international search report

12.08.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-2016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.

PCT/US 94/04215

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 363 212 (MITSUI TOATSU CHEMICALS) 11 April 1990 cited in the application *Document* & US,A,5 112 817 (FUKAZAWA, NOBUYUKI ET. AL.) 12 May 1992 ---	1-20
P,A	EP,A,0 575 890 (MITSUI TOATSU CHEMICALS) 29 December 1993 *Document* -----	1-17

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 94/ 04215

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-13
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 8-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 94/04215

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-3133925		NONE	
EP-A-0229623	22-07-87	DE-A- 3600390 AU-A- 6741687 JP-A- 62167762 US-A- 4918073	16-07-87 16-07-87 24-07-87 17-04-90
FR-A-2112509	16-06-72	BE-A- 774860 DE-A- 2155132 GB-A- 1317034	03-05-72 29-06-72 16-05-73
FR-A-2567885	24-01-86	BE-A- 902897 CH-A- 665208 DE-A- 3524955 GB-A, B 2163150 JP-A- 61037765	15-01-86 29-04-88 30-01-86 19-02-86 22-02-86
EP-A-0363212	11-04-90	JP-A- 3101662 US-A- 5112817 US-A- 5204348	26-04-91 12-05-92 20-04-93
US-A-5112817	12-05-92	EP-A- 0363212 JP-A- 3101662 US-A- 5204348	11-04-90 26-04-91 20-04-93
EP-A-0575890	29-12-93	JP-A- 6001768	11-01-94